C4 Therapeutics and Roche Expand Partnership with $1 Billion+ DAC Collaboration
Key Insights
C4 Therapeutics has entered a new collaboration agreement with Roche to develop degrader-antibody conjugates (search) (DACs), combining targeted protein degradation with antibody-drug conjugation technology.
The partnership focuses on two undisclosed oncology targets, with C4T receiving $20 million upfront and eligibility for over $1 billion in milestone payments plus tiered royalties.
DACs represent an emerging cancer therapy modality that leverages degrader payloads' catalytic mechanism to potentially overcome limitations of traditional ADCs.
C4 Therapeutics has announced a new collaboration agreement with Roche to advance research in degrader-antibody conjugates (search) (DACs), an emerging cancer therapy modality that combines the precision of targeted protein degradation with antibody delivery systems. The partnership represents a significant expansion of the companies' decade-long relationship and positions both firms at the forefront of next-generation oncology therapeutics.
Financial Terms and Structure
Under the agreement, C4 Therapeutics will receive a $20 million upfront payment for two oncology programs targeting undisclosed cancer-related proteins. The collaboration includes an option for Roche to add a third target, which would trigger an additional payment to C4T. Across all programs, C4 Therapeutics is eligible to receive over $1 billion in discovery, regulatory, and commercial milestone payments, plus tiered royalties on future sales.
The financial structure reflects the significant potential both companies see in the DAC modality. "For the past decade, C4T and Roche have worked together to drive research in targeted protein degradation and to establish this modality as a new way to treat cancer," said Andrew Hirsch, president and chief executive officer of C4 Therapeutics.
Technology Integration and Development Approach
The collaboration leverages complementary expertise from both organizations. C4 Therapeutics will utilize its proprietary TORPEDO platform (search) to design degrader payload candidates, while Roche will handle antibody selection, design, and conjugation processes. Roche will also be responsible for advancing DAC candidates through preclinical and clinical development phases, as well as eventual commercialization.
This division of responsibilities builds on each company's core strengths. C4T's TORPEDO platform (search) integrates DNA-encoded library technology, Cereblon (search) toolkit capabilities, diverse chemical libraries, and AI-driven ternary complex models to create highly selective degraders. Roche brings extensive experience in antibody-drug conjugate development and clinical advancement.
DAC Technology Advantages
Degrader-antibody conjugates (search) represent a potential advancement over traditional ADCs, which have historically faced challenges with limited therapeutic margins. DACs utilize degrader payloads that target specific cellular dependencies, potentially offering superior therapeutic indices compared to conventional cytotoxic payloads.
The catalytic mechanism of action inherent to degrader payloads distinguishes DACs from traditional approaches. This catalytic efficiency, combined with the targeted delivery capabilities of antibodies, creates what the companies describe as "a powerful new modality that can offer transformative medicines for patients."
Partnership History and Strategic Context
This collaboration marks the third agreement between C4 Therapeutics and Roche, building on a partnership that began in 2016. "Roche has been a believer in targeted protein degradation and its potential for differentiation early on, when partnering with C4T for the first time in 2016," said Boris Zaïtra, head of corporate business development at Roche.
The relationship demonstrates Roche's continued commitment to targeted protein degradation as a therapeutic modality. Zaïtra noted that the partnership "is built on a decade of trust and shared scientific ambition" and represents an expansion into "the emerging modality of degrader-antibody conjugates (search)."
Market Response and Future Outlook
Following the announcement, C4 Therapeutics shares rose 2.44 percent to $2.97 in pre-market trading, reflecting investor confidence in the collaboration's potential. The partnership positions both companies to explore new therapeutic approaches for hard-to-treat cancers while leveraging established expertise in their respective technology platforms.
The collaboration's focus on undisclosed oncology targets suggests the companies are targeting specific cancer dependencies that may benefit from the unique properties of degrader-antibody conjugates (search). The option for a third target provides flexibility to expand the partnership based on initial program success and emerging opportunities in the oncology landscape.